异体干细胞治疗急性缺血性卒中:2/3期TREASURE随机临床试验
TREASURE研究为在日本44个中心开展的多中心、双盲、平行组、安慰剂对照2/3期随机临床试验,纳入206例急性缺血性卒中患者,在发病18至36小时内静脉给予MultiStem(HLCM051)或安慰剂。结果显示两组第90天优良结局比例无显著差异(12例[11.5%] vs 10例[9.8%],P=0.90;校正风险差0.5%[95%CI,-7.3%至8.3%]),不良事件频率相似。结论认为该治疗安全但未改善短期结局,需进一步研究特定患者是否获益。
要点
- MultiStem在缺血性卒中发病18至36小时内静脉给药安全,但未改善第90天优良结局。
- 第90天优良结局比例MultiStem组12例(11.5%)vs 安慰剂组10例(9.8%),无显著差异。
- 两组不良事件频率相似,主要和次要终点均无组间差异。
核心结论
- 在发病18至36小时内静脉给予异体细胞治疗是安全的,但未改善短期结局。
- 需要进一步研究以确定MultiStem治疗对符合特定标准的缺血性卒中患者是否具有有益效应,如本研究的探索性分析所示。
研究设计与样本
- TREASURE为多中心、双盲、平行组、安慰剂对照2/3期随机临床试验,在日本44个学术和临床中心开展,时间为2017年11月15日至2022年3月29日。
- 纳入标准为年龄20岁及以上、基线NIHSS评分8-20分、弥散加权磁共振成像确认累及大脑皮质且长轴大于2cm的急性梗死、卒中前mRS评分为0或1。
- 共纳入206例患者,MultiStem组104例,安慰剂组102例;平均年龄76.5岁(范围35-95岁),男性112例(54.4%)。
- 干预为发病18至36小时内静脉给予单次1单位12亿个细胞的MultiStem或静脉安慰剂。
- 主要终点为安全性和第90天优良结局(mRS≤1、NIHSS≤1和Barthel指数≥95的复合终点);次要终点包括第365天优良结局、第90天和第365天mRS分布、第90天mRS 0-1和0-2。
主要发现
- 第90天优良结局比例MultiStem组12例(11.5%)vs 安慰剂组10例(9.8%),无显著差异(P=0.90;校正风险差0.5%[95%CI,-7.3%至8.3%])。
- 主要和次要终点均无组间差异。
- 不良事件频率在治疗组间相似。
局限性
- 需要进一步研究以确定MultiStem治疗对符合特定标准的缺血性卒中患者是否具有有益效应,如本研究的探索性分析所示。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Cell therapy is a promising treatment approach for stroke and other diseases. However, it is unknown whether MultiStem (HLCM051), a bone marrow-derived, allogeneic, multipotent adult progenitor cell product, has the potential to treat ischemic stroke. OBJECTIVE: To assess the efficacy and safety of MultiStem when administered within 18 to 36 hours of ischemic stroke onset. DESIGN, SETTING, AND PARTICIPANTS: The Treatment Evaluation of Acute Stroke Using Regenerative Cells (TREASURE) multicenter, double-blind, parallel-group, placebo-controlled phase 2/3 randomized clinical trial was conducted at 44 academic and clinical centers in Japan between November 15, 2017, and March 29, 2022. Inclusion criteria were age 20 years or older, presence of acute ischemic stroke (National Institutes of Health Stroke Scale [NIHSS] score of 8-20 at baseline), confirmed acute infarction involving the cerebral cortex and measuring more than 2 cm on the major axis (determined with diffusion-weighted magnetic resonance imaging), and a modified Rankin Scale (mRS) score of 0 or 1 before stroke onset. Data analysis was performed between May 9 and August 15, 2022. EXPOSURE: Patients were randomly assigned to either intravenous MultiStem in 1 single unit of 1.2 billion cells or intravenous placebo within 18 to 36 hours of ischemic stroke onset. MAIN OUTCOMES AND MEASURES: The primary end points were safety and excellent outcome at day 90, measured as a composite of a modified Rankin Scale (mRS) score of 1 or less, a NIHSS score of 1 or less, and a Barthel index score of 95 or greater. The secondary end points were excellent outcome at day 365, mRS score distribution at days 90 and 365, and mRS score of 0 to 1 and 0 to 2 at day 90. Statistical analysis of efficacy was performed using the Cochran-Mantel-Haenszel test. RESULTS: This study included 206 patients (104 received MultiStem and 102 received placebo). Their mean age was 76.5 (range, 35-95) years, and more than half of patients were men (112 [54.4%]). There were no between-group differences in primary and secondary end points. The proportion of excellent outcomes at day 90 did not differ significantly between the MultiStem and placebo groups (12 [11.5%] vs 10 [9.8%], P = .90; adjusted risk difference, 0.5% [95% CI, -7.3% to 8.3%]). The frequency of adverse events was similar between treatment groups. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, intravenous administration of allogeneic cell therapy within 18 to 36 hours of ischemic stroke onset was safe but did not improve short-term outcomes. Further research is needed to determine whether MultiStem therapy for ischemic stroke has a beneficial effect in patients who meet specific criteria, as indicated by the exploratory analyses in this study. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02961504.
引用
- Houkin K, Osanai T, Uchiyama S, et al. Allogeneic Stem Cell Therapy for Acute Ischemic Stroke: The Phase 2/3 TREASURE Randomized Clinical Trial. JAMA Neurol. 2024. PMID: 38227308. doi:10.1001/jamaneurol.2023.5200
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。